AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16844506 — intervention group
Group type: COMPARATOR
Intervention: Control group (no diagram)
Number of subjects: 88
Study 16844506 — intervention group
Group type: EXPERIMENTAL
Intervention: Mole-mapping diagram (altered images)
Number of subjects: 88
Study 16844506 — intervention group
Group type: COMPARATOR
Intervention: Control group (altered images)
Number of subjects: 88
Study 12787117 — intervention group
Group type: EXPERIMENTAL
Intervention: Objective measurement of clinical signs
Number of subjects: 93
Study 12787117 — intervention group
Group type: EXPERIMENTAL
Intervention: Published severity scale
Number of subjects: 93
Study 12787117 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified versions of published scales
Number of subjects: 93
Study 12787117 — intervention group
Group type: EXPERIMENTAL
Intervention: Unnamed scales
Number of subjects: 93
Study 12787117 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient symptoms
Number of subjects: 93
Study 12787117 — intervention group
Group type: EXPERIMENTAL
Intervention: Disease extent
Number of subjects: 93
Study 12787117 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life
Number of subjects: 93
Study 12787117 — intervention group
Group type: EXPERIMENTAL
Intervention: Unvalidated outcome measures
Number of subjects: 93
Study 10770423 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic photopheresis
Number of subjects: 23
Study 10770423 — intervention group
Group type: COMPARATOR
Intervention: Control group (cyclosporine, azathioprine, prednisone without photopheresis)
Number of subjects: 23
Study 8848847 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with clubfoot
Number of subjects: 21
Study 8848847 — intervention group
Group type: COMPARATOR
Intervention: Children without deformity (control group)
Number of subjects: 21
Study 8403911 — intervention group
Group type: EXPERIMENTAL
Intervention: Copper intrauterine device (Cu IUD)
Number of subjects: 0
Study 3512619 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose aspirin 0.5 mg/kg/d
Number of subjects: 10
Study 3512619 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose aspirin 15 mg/kg/d
Number of subjects: 10
Study 3512619 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose aspirin 0.5 mg/kg/d and 15 mg/kg/d
Number of subjects: 10
Study 3512619 — intervention group
Group type: COMPARATOR
Intervention: Furosemide
Number of subjects: 10
Study 29621284 — intervention group
Group type: EXPERIMENTAL
Intervention: Illness Management and Recovery (IMR) program
Number of subjects: 198
Study 29621284 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 198
Study 27538952 — intervention group
Group type: EXPERIMENTAL
Intervention: Xinyue capsules (1.8 g/day, three times daily for up to 24 weeks)
Number of subjects: 1100
Study 27538952 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules (three times daily for up to 24 weeks)
Number of subjects: 1100
Study 25431770 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 g/day essential amino acids (EAAs); n=19
Number of subjects: 38
Study 25431770 — intervention group
Group type: COMPARATOR
Intervention: Isocaloric placebo (maltodextrin); n=19
Number of subjects: 38
Study 25431770 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls; n=8
Number of subjects: 38
Study 22209126 — intervention group
Group type: EXPERIMENTAL
Intervention: telephone-delivered collaborative care intervention for depression
Number of subjects: 302
Study 22209126 — intervention group
Group type: COMPARATOR
Intervention: usual care by primary care physicians
Number of subjects: 302
Study 20449532 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-protein dietetic foods
Number of subjects: 49
Study 20449532 — intervention group
Group type: COMPARATOR
Intervention: Low-protein diet
Number of subjects: 49
Study 17449306 — intervention group
Group type: EXPERIMENTAL
Intervention: Neramexane (40 mg p.o.)
Number of subjects: 18
Study 17449306 — intervention group
Group type: EXPERIMENTAL
Intervention: Flupirtine (100 mg)
Number of subjects: 18
Study 17449306 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 15946202 — intervention group
Group type: COMPARATOR
Intervention: Prophylactic doses of nadroparin (2850 a‐Xa IU)
Number of subjects: 164
Study 15946202 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic doses of nadroparin (body-weight adjusted)
Number of subjects: 164
Study 12891111 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-administered WIQ
Number of subjects: 60
Study 12891111 — intervention group
Group type: COMPARATOR
Intervention: Telephone-administered WIQ
Number of subjects: 60
Study 10335905 — intervention group
Group type: EXPERIMENTAL
Intervention: (S)-propranolol 40 mg
Number of subjects: 15
Study 10335905 — intervention group
Group type: EXPERIMENTAL
Intervention: (S)-atenolol 50 mg
Number of subjects: 15
Study 10335905 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 15
Study 10335905 — intervention group
Group type: EXPERIMENTAL
Intervention: (R)-propranolol 40 mg
Number of subjects: 15
Study 10335905 — intervention group
Group type: EXPERIMENTAL
Intervention: (R)-atenolol 50 mg
Number of subjects: 15
Study 10335905 — intervention group
Group type: EXPERIMENTAL
Intervention: (R,S)-carvedilol 25 mg
Number of subjects: 15
Study 10335905 — intervention group
Group type: EXPERIMENTAL
Intervention: (R,S)-verapamil 120 mg
Number of subjects: 15
Study 8724530 — intervention group
Group type: EXPERIMENTAL
Intervention: Amsacrine (AMSA) 75 mg/m2/day x 4 plus continuous infusion high-dose cytarabine (CIHDAC) 1.5 g/m2/day x 4
Number of subjects: 204
Study 8724530 — intervention group
Group type: COMPARATOR
Intervention: Continuous infusion high-dose cytarabine (CIHDAC) alone
Number of subjects: 204
Study 8724530 — intervention group
Group type: EXPERIMENTAL
Intervention: Amsacrine (AMSA) plus CIHDAC
Number of subjects: 204
Study 1748254 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet-plus-exercise (upper-arm exercise)
Number of subjects: 20
Study 1748254 — intervention group
Group type: COMPARATOR
Intervention: Diet (control group)
Number of subjects: 20
Study 6137327 — intervention group
Group type: EXPERIMENTAL
Intervention: Indapamide (2.5 mg per day)
Number of subjects: 26
Study 6137327 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide
Number of subjects: 26
Study 6137327 — intervention group
Group type: COMPARATOR
Intervention: Placebo (4-week period)
Number of subjects: 26
Study 6137327 — intervention group
Group type: EXPERIMENTAL
Intervention: Indapamide (used alone or in combination)
Number of subjects: 26
Study 6137327 — intervention group
Group type: EXPERIMENTAL
Intervention: Indapamide
Number of subjects: 26
Study 31821355 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.0% non-chemically modified sodium hyaluronate (SH)
Number of subjects: 292
Study 31821355 — intervention group
Group type: COMPARATOR
Intervention: 0.8% hylan G-F 20 (control)
Number of subjects: 292
Study 29916110 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous carbetocin (100 mcg)
Number of subjects: 350
Study 29916110 — intervention group
Group type: COMPARATOR
Intervention: Intravenous oxytocin (5 U)
Number of subjects: 350
Study 26399485 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducational intervention
Number of subjects: 53
Study 26399485 — intervention group
Group type: COMPARATOR
Intervention: Education only
Number of subjects: 53
Study 24769332 — intervention group
Group type: EXPERIMENTAL
Intervention: AXT914 45 mg
Number of subjects: 0
Study 24769332 — intervention group
Group type: EXPERIMENTAL
Intervention: AXT914 60 mg
Number of subjects: 0
Study 24769332 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 24769332 — intervention group
Group type: COMPARATOR
Intervention: Teriparatide (20 μg Forteo/PTH(1-34) fragment)
Number of subjects: 0
Study 21701082 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilostazol (200 mg daily, n=24)
Number of subjects: 49
Study 21701082 — intervention group
Group type: COMPARATOR
Intervention: Aspirin (100 mg daily, n=25)
Number of subjects: 49
Study 19493295 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based sex therapy
Number of subjects: 98
Study 19493295 — intervention group
Group type: COMPARATOR
Intervention: Waiting list (control)
Number of subjects: 98
Study 17470830 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab (5 mg/kg of body weight)
Number of subjects: 44
Study 17470830 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 15138905 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulating catheter-guided perineural placement
Number of subjects: 20
Study 15138905 — intervention group
Group type: COMPARATOR
Intervention: Nonstimulating catheter placement
Number of subjects: 20
Study 11510062 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v.‐PCA (+) combined with CEA
Number of subjects: 108
Study 11510062 — intervention group
Group type: COMPARATOR
Intervention: i.v.‐PCA (‐)
Number of subjects: 108
Study 11510062 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v.‐PCA (+)
Number of subjects: 108
Study 9669006 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 40
Study 9669006 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 40
Study 7834003 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-mL saline instillation
Number of subjects: 10
Study 7834003 — intervention group
Group type: EXPERIMENTAL
Intervention: Suction catheter insertion
Number of subjects: 10
Study 3239468 — intervention group
Group type: EXPERIMENTAL
Intervention: Hunger factor
Number of subjects: 0
Study 29915435 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention using wearable monitoring devices with IoT systems and monthly remote health guidance from a public health nurse.
Number of subjects: 145
Study 29915435 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 145
Study 28628763 — intervention group
Group type: EXPERIMENTAL
Intervention: Metacognitive Training for Depression (D-MCT)
Number of subjects: 154
Study 28628763 — intervention group
Group type: COMPARATOR
Intervention: Active control intervention (walking and psychoeducation sessions)
Number of subjects: 154
Study 26420199 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional intervention focusing on education to increase dietary intake of whole grain, vegetables, and fruits, and to reduce sodium, simple sugar, and dietary fat (especially cooking oil and pork lard).
Number of subjects: 235
Study 26420199 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional intervention (same as above).
Number of subjects: 235
Study 26420199 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 235
Study 23190777 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV13
Number of subjects: 0
Study 23190777 — intervention group
Group type: COMPARATOR
Intervention: PCV7
Number of subjects: 0
Study 21911890 — intervention group
Group type: EXPERIMENTAL
Intervention: Low Carbohydrate Diet (LCD)
Number of subjects: 59
Study 21911890 — intervention group
Group type: COMPARATOR
Intervention: Low Fat Diet (LFD)
Number of subjects: 59
Study 18608135 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan 50 mg
Number of subjects: 183
Study 18608135 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisoprolol 5 mg
Number of subjects: 183
Study 18608135 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine 5 mg
Number of subjects: 183
Study 18608135 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HCTZ) 25 mg
Number of subjects: 183
Study 18608135 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 183
Study 16567711 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine treatment
Number of subjects: 38
Study 16567711 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 38
Study 12620952 — intervention group
Group type: EXPERIMENTAL
Intervention: Bronchodilator premedication (albuterol or ipratropium)
Number of subjects: 109
Study 12620952 — intervention group
Group type: COMPARATOR
Intervention: Placebo (nebulized saline)
Number of subjects: 109
Study 12620952 — intervention group
Group type: EXPERIMENTAL
Intervention: Endotracheal intubation
Number of subjects: 109
Study 12620952 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative capnometry
Number of subjects: 109
Study 10695689 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose antihypertensive therapy
Number of subjects: 3975
Study 10695689 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3975
Study 9350317 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative treatment
Number of subjects: 0
Study 9350317 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8461472 — intervention group
Group type: EXPERIMENTAL
Intervention: 7 g/d of a 85% omega-3 fatty acid fish oil concentrate
Number of subjects: 14
Study 8461472 — intervention group
Group type: COMPARATOR
Intervention: Control group (7 volunteers)
Number of subjects: 14
Study 3026009 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulbactam/ampicillin (1 g of sulbactam and 2 g of ampicillin three times a day for two weeks)
Number of subjects: 22
Study 3026009 — intervention group
Group type: COMPARATOR
Intervention: Cefotaxime (2 g three times a day for two weeks)
Number of subjects: 22
Study 29199784 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual counselling sessions via videoconferencing calls
Number of subjects: 33
Study 29199784 — intervention group
Group type: EXPERIMENTAL
Intervention: Wearable PA monitors
Number of subjects: 33
Study 29199784 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 33
Study 29803269 — intervention group
Group type: EXPERIMENTAL
Intervention: BLISS (modified Baby-Led Weaning)
Number of subjects: 206
Study 29803269 — intervention group
Group type: COMPARATOR
Intervention: Control (traditional spoon-feeding)
Number of subjects: 206
Study 26289058 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational video on breastfeeding
Number of subjects: 522
Study 26289058 — intervention group
Group type: COMPARATOR
Intervention: Educational video on prenatal nutrition and exercise
Number of subjects: 522
Study 24705018 — intervention group
Group type: EXPERIMENTAL
Intervention: Special whey protein bar (1:1 carbohydrate to protein ratio)
Number of subjects: 31
Study 24705018 — intervention group
Group type: EXPERIMENTAL
Intervention: Commercially available tomato juice
Number of subjects: 31
Study 24705018 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 31
Study 22146812 — intervention group
Group type: EXPERIMENTAL
Intervention: Expandable pedicle screws (EPS)
Number of subjects: 157
Study 22146812 — intervention group
Group type: COMPARATOR
Intervention: Conventional pedicle screws (CPS)
Number of subjects: 157
Study 20422202 — intervention group
Group type: EXPERIMENTAL
Intervention: Tissue Harmonic Imaging (THI)
Number of subjects: 313
Study 20422202 — intervention group
Group type: COMPARATOR
Intervention: Conventional B-scan (BSCAN)
Number of subjects: 313
Study 20422202 — intervention group
Group type: EXPERIMENTAL
Intervention: Compound Imaging (CI)
Number of subjects: 313
Study 20422202 — intervention group
Group type: EXPERIMENTAL
Intervention: Tissue Harmonic Compound Imaging (THICI)
Number of subjects: 313
Study 17208334 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapsone gel, 5%
Number of subjects: 3010
Study 17208334 — intervention group
Group type: COMPARATOR
Intervention: Vehicle gel
Number of subjects: 3010
Study 15076782 — intervention group
Group type: EXPERIMENTAL
Intervention: Foot cooling (FC)
Number of subjects: 12
Study 15076782 — intervention group
Group type: COMPARATOR
Intervention: No foot cooling (NC)
Number of subjects: 12
Study 12460519 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant human growth hormones (rhGH) 9 U/d
Number of subjects: 24
Study 12460519 — intervention group
Group type: COMPARATOR
Intervention: isotonic saline
Number of subjects: 24
Study 9808825 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored counseling and guide (Pathways to Freedom)
Number of subjects: 1422
Study 9808825 — intervention group
Group type: COMPARATOR
Intervention: Standard counseling and guide (Clearing the Air)
Number of subjects: 1422
Study 7700763 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (0.5 mg/kg/day intravenously for 3 days, 0.25 mg/kg/day for 3 days, and 0.1 mg/kg/day for 1 day)
Number of subjects: 43
Study 7700763 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 43
Study 7700763 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 43
Study 2199618 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy (six IV cyclophosphamide, methotrexate, and fluorouracil courses followed by four IV epirubicin courses)
Number of subjects: 510
Study 2199618 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (5 years treatment)
Number of subjects: 510
Study 2199618 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy plus Tamoxifen
Number of subjects: 510
Study 2199618 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy (with or without tamoxifen)
Number of subjects: 510
Study 2199618 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen alone
Number of subjects: 510
Study 276963 — intervention group
Group type: EXPERIMENTAL
Intervention: Xylocitin with adrenalin (1:80 000)
Number of subjects: 0
Study 276963 — intervention group
Group type: EXPERIMENTAL
Intervention: Xylocitin with noradrenalin (1:20 000)
Number of subjects: 0
Study 31112273 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP‐1 infusion
Number of subjects: 11
Study 31112273 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 11
Study 28374695 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytoflavin 10 ml/day
Number of subjects: 86
Study 28374695 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytoflavin 20 ml/day
Number of subjects: 86
Study 28374695 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 86
Study 25888067 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel monotherapy
Number of subjects: 18
Study 25888067 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of docetaxel + sunitinib
Number of subjects: 18
Study 23418985 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute tryptophan depletion (ATD)
Number of subjects: 22
Study 23418985 — intervention group
Group type: COMPARATOR
Intervention: Tryptophan-balanced amino acid load (BAL)
Number of subjects: 22
Study 21421600 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate percutaneous coronary intervention (PCI) strategy
Number of subjects: 352
Study 21421600 — intervention group
Group type: COMPARATOR
Intervention: Delayed PCI strategy (next working day)
Number of subjects: 352
Study 21421600 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with major bleeding
Number of subjects: 352
Study 21421600 — intervention group
Group type: COMPARATOR
Intervention: Patients without major bleeding
Number of subjects: 352
Study 21421600 — intervention group
Group type: EXPERIMENTAL
Intervention: Major bleeding
Number of subjects: 352
Study 19216685 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine monitoring (n = 17)
Number of subjects: 35
Study 19216685 — intervention group
Group type: COMPARATOR
Intervention: Conventional follow-up (n = 18)
Number of subjects: 35
Study 17659845 — intervention group
Group type: EXPERIMENTAL
Intervention: PCOS group
Number of subjects: 457
Study 17659845 — intervention group
Group type: COMPARATOR
Intervention: Control group (without PCOS)
Number of subjects: 457
Study 16042327 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone treatment (GHTX)
Number of subjects: 32
Study 16042327 — intervention group
Group type: COMPARATOR
Intervention: Non-treatment group (NonTX)
Number of subjects: 32
Study 12476037 — intervention group
Group type: EXPERIMENTAL
Intervention: 800-mg oral dose of telithromycin
Number of subjects: 24
Study 12476037 — intervention group
Group type: COMPARATOR
Intervention: Intravenous infusion of 400 mg telithromycin (young) or 480 mg telithromycin (elderly)
Number of subjects: 24
Study 10731130 — intervention group
Group type: EXPERIMENTAL
Intervention: Tazarotene plus mid- or high-potency topical corticosteroid
Number of subjects: 698
Study 10731130 — intervention group
Group type: COMPARATOR
Intervention: Tazarotene plus placebo
Number of subjects: 698
Study 10731130 — intervention group
Group type: EXPERIMENTAL
Intervention: Tazarotene alternating with high-potency topical corticosteroid
Number of subjects: 698
Study 10731130 — intervention group
Group type: COMPARATOR
Intervention: Tazarotene alternating with mid-potency corticosteroid
Number of subjects: 698
Study 10731130 — intervention group
Group type: EXPERIMENTAL
Intervention: Tazarotene plus low-, mid-, and high-potency corticosteroid
Number of subjects: 698
Study 8525815 — intervention group
Group type: COMPARATOR
Intervention: Conventional running shoes
Number of subjects: 35
Study 8525815 — intervention group
Group type: EXPERIMENTAL
Intervention: Running shoes with a negative sole
Number of subjects: 35
Study 2024970 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine and proguanil (Ch-P)
Number of subjects: 130
Study 2024970 — intervention group
Group type: COMPARATOR
Intervention: No prophylaxis (Control)
Number of subjects: 130
Study 6892711 — intervention group
Group type: EXPERIMENTAL
Intervention: Free milk supplement (190 ml daily for six school terms)
Number of subjects: 581
Study 6892711 — intervention group
Group type: COMPARATOR
Intervention: Control group (no free milk)
Number of subjects: 581
Study 31434111 — intervention group
Group type: EXPERIMENTAL
Intervention: Active homeopathic medicine
Number of subjects: 105
Study 31434111 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 105
Study 28506540 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive parenting program (12 individual sessions, observational sessions with live coaching and video feedback)
Number of subjects: 40
Study 28506540 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 40
Study 26017649 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% lidocaine with 1:100,000 epinephrine
Number of subjects: 70
Study 26017649 — intervention group
Group type: COMPARATOR
Intervention: 2% lidocaine without epinephrine
Number of subjects: 70
Study 24337619 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy (CEA)
Number of subjects: 0
Study 24337619 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid artery stenting (CAS)
Number of subjects: 0